Nefelie Charalabopoulou brings to the firm more than 15 years of experience in advising multinational and domestic life sciences companies on key transactions, cross border issues and day to day operations. She delivers the full spectrum of services to clients throughout the corporate and product life cycle. Her representations have involved the pharmaceutical, medical device, cannabis, and cosmetic industries, on a wide range of regulatory, compliance and industry-specific commercial matters.
Julia Pournara, partner, head of our Healthcare Practice, was a speaker at the 3rd MedTech Conference sponsored by SEIV, the Association of Health Research & Biotechnology Industry and held on 18 October 2017 in Athens. Her speech focused on the changes that importers and distributors of medical devices in Greece will encounter as a result of the new rules established by the Medical Devices Regulation no 2017/745 (MDR).
For a copy of Julia Pournara’s presentation (in Greek) please click here.
Zepos & Yannopoulos advised ICU in regard to the acquisition of Pfizer Ηospira Infusion Systems. ICU Medical is a large multinational company specialised in infusion therapies and this acquisition makes it one of the world’s leading pure-play infusion therapy companies. Zepos & Yannopoulos was involved in all aspects applicable to the Greek jurisdiction, including corporate, regulatory and public procurement implications and also covered the different options for structuring the marketing and distribution model for the local market.
Julia Pournara, partner, head of our Healthcare practice group, was a speaker at the "1st Pharmaceutical Law Conference” organised by the Hellenic Association of Pharmaceutical Companies (SFEE). Her presentation analysed the inherent legal risks of Patient Assistance Programs.
To download a copy of her presentation (in Greek) please click below.
Zepos & Yannopoulos advised Teva on the corporate and regulatory matters pertinent to the divestment of certain businesses which was dictated by the Commitments defined by the EU Commission Decision on the acquisition of Allergan by Teva. Teva Pharmaceutical Industries Ltd is a leading global pharmaceutical company, listed on NYSE, and engaged in the development, production and marketing of affordable generic drugs, as well as of innovative and specialty pharmaceuticals and active pharmaceutical ingredients.